Background: Health disparities have a major impact in the quality of life and clinical care
received by minorities in the United States. Pulmonary arterial hypertension (PAH) is a rare …

Conflict of interest statements: Dr RJ Bernardo serves on the medical advisory board for
Janssen Pharmaceuticals. Dr VA de Jesus Perez has no conflict of interest to declare …

BACKGROUND Prior research has suggested that the prevalence and outcomes of
pulmonary arterial hypertension (PAH) may vary by race or ethnicity. However, these studies …

Rationale: Lower socioeconomic status (SES) confers a heightened risk of common
cardiovascular and pulmonary diseases and increased mortality. The association of SES …

In the past decade and a half, the introduction of new therapeutic agents has revolutionized
the management of pulmonary arterial hypertension (PAH). These new treatment options …

Rationale: There is a noticeable underrepresentation of minorities in clinical trials and
registries in pulmonary arterial hypertension (PAH). Prior studies evaluating the association …

This study explores the racial and ethnic differences in presentation, severity, and treatment
of patients with pulmonary arterial hypertension (PAH) in a large multicenter registry. African …

The Black Lives Matter protests and COVID-19 pandemic have brought widening disparities
experienced by disadvantaged communities of color to the forefront, generating much …

Rationale: Limited information is available on racial/ethnic differences in pulmonary arterial
hypertension (PAH). Objectives: Determine effects of race/ethnicity and ancestry on mortality …

Background Pulmonary arterial hypertension (PAH) is a life-threatening disease that affects
more women than men. The reasons for the female preponderance are unclear, and there …